Trials / Completed
CompletedNCT01499368
A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess and Compare to the Efficacy and Safety of Lafutidine, Famotidine and Omeprazole-referenced in Korean Erosive Esophagitis Patients
A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess and Compare to the Efficacy and Safety of Lafutidine, Famotidine and Omeprazole-referenced in Koran Erosive Esophagitis Patients
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 495 (actual)
- Sponsor
- Boryung Pharmaceutical Co., Ltd · Industry
- Sex
- All
- Age
- 20 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the healing rate and safety of Lafutidine in erosive esophagitis
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lafutidine | Lafutidine 20mg/day |
| DRUG | Famotidine | Famotidine 40mg/day |
| DRUG | Omeprazole | Omeprazole 20mg/day |
Timeline
- Start date
- 2011-11-01
- Primary completion
- 2012-11-01
- Completion
- 2012-11-01
- First posted
- 2011-12-26
- Last updated
- 2025-01-15
- Results posted
- 2020-09-16
Source: ClinicalTrials.gov record NCT01499368. Inclusion in this directory is not an endorsement.